垂体腺苷酸环化酶激活肽：在中风和痴呆中的保护作用。

Pituitary adenylate cyclase-activating polypeptide: Protective effects in stroke and dementia.

机构信息

Department of Oral Anatomy and Developmental Biology, Showa University School of Dentistry, Shinagawa-ku, Tokyo, Japan.

Division of Gerontology and Geriatric Medicine, Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA.

出版信息

Peptides. 2020 Aug;130:170332. doi: 10.1016/j.peptides.2020.170332. Epub 2020 May 21.

DOI:10.1016/j.peptides.2020.170332

PMID:32445876

Abstract

Evidence shows that pituitary adenylate cyclase-activating polypeptide (PACAP) improves stroke outcomes and dementia. The blood-brain barrier (BBB) controls the peptide and regulatory protein exchange between the central nervous system and the blood; the transport of these regulatory substances across the BBB has been altered in animal models of stroke and Alzheimer's disease (AD). PACAP is a powerful neurotrophin that can cross the BBB, which may aid in the therapy of neurodegenerative diseases, including stroke and AD. PACAP may function as a potential drug in the treatment, prevention, or management of stroke and AD and other neurodegenerative conditions. Here, we review the effects of PACAP in studies on stroke and dementias.

摘要

证据表明，垂体腺苷酸环化酶激活肽（PACAP）可改善中风和痴呆的预后。血脑屏障（BBB）控制着中枢神经系统和血液之间的肽和调节蛋白交换；在中风和阿尔茨海默病（AD）的动物模型中，这些调节物质的跨 BBB 转运已经发生改变。PACAP 是一种强大的神经营养因子，可以穿过 BBB，这可能有助于治疗神经退行性疾病，包括中风和 AD。PACAP 可能作为一种潜在的药物，用于治疗、预防或管理中风、AD 和其他神经退行性疾病。在这里，我们综述了 PACAP 在中风和痴呆研究中的作用。